Suppr超能文献

多巴胺和雌二醇对垂体中活性和总转化生长因子-β1 的调节存在差异。

Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.

机构信息

Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Vuelta de Obligado 2490, Buenos Aires 1428, Argentina.

出版信息

Endocrinology. 2011 Jul;152(7):2722-30. doi: 10.1210/en.2010-1464. Epub 2011 Apr 26.

Abstract

Dopamine, acting through the dopamine type 2 receptor (Drd2), is the main inhibitor of pituitary prolactin (PRL) secretion and lactotroph proliferation. TGF-β1 is involved, at least in part, in mediating these actions. It was described that TGF-β1 synthesis in rat pituitary lactotrophs is up-regulated by dopamine and down-regulated by estradiol. TGF-β1 is secreted as a large latent complex. The local regulation of cytokine activation in the pituitary has not yet been explored. In this work, we studied pituitary active and total TGF-β1 content, as well as TGF-β1 mRNA, and the in vivo role of dopamine and estradiol on pituitary TGF-β1 levels. Adult female mice (wild type), and female mice with a null mutation in the Drd2 (Drd2(-/-)), were used. The loss of dopaminergic tone induced a decrease in TGF-β1 mRNA expression, in active and total cytokine content, and in TGF-β type II receptor expression. Dopamine regulation of pituitary TGF-β1 activation process was inferred by the inhibition of active cytokine by in vivo sulpiride treatment. Interestingly, in the absence of dopaminergic tone, estradiol induced a strong increase in active TGF-β1. PRL secretion correlated with active, but not total cytokine. TGF-β1 inhibitory action on lactotroph proliferation and PRL secretion was decreased in Drd2(-/-) pituitary cells, in correlation with decreased TGF-β type II receptor. The study of the TGF-β1 activation process and its regulation is essential to understand the cytokine activity. As an intermediary of dopamine inhibition of lactotroph function, TGF-β1 and local activators may be important targets in the treatment of dopamine agonist-resistant prolactinomas.

摘要

多巴胺通过多巴胺 2 型受体(Drd2)发挥作用,是抑制垂体泌乳素(PRL)分泌和催乳素细胞增殖的主要物质。转化生长因子-β1(TGF-β1)至少部分参与了这些作用的介导。研究表明,多巴胺可上调大鼠垂体催乳素细胞中 TGF-β1 的合成,而雌二醇则下调其合成。TGF-β1 以大潜伏复合物的形式分泌。细胞因子在垂体中的局部调节尚未得到探索。在这项工作中,我们研究了垂体中活性和总 TGF-β1 含量,以及 TGF-β1 mRNA,以及多巴胺和雌二醇对垂体 TGF-β1 水平的体内作用。使用成年雌性小鼠(野生型)和 Drd2 基因缺失(Drd2(-/-))的雌性小鼠。多巴胺能神经张力的丧失导致 TGF-β1 mRNA 表达、活性和总细胞因子含量以及 TGF-β 型 II 受体表达下降。通过体内舒必利处理抑制活性细胞因子,推断出多巴胺对垂体 TGF-β1 激活过程的调节作用。有趣的是,在缺乏多巴胺能神经张力的情况下,雌二醇会强烈增加活性 TGF-β1。PRL 分泌与活性细胞因子相关,而与总细胞因子无关。在 Drd2(-/-)垂体细胞中,TGF-β1 对催乳素细胞增殖和 PRL 分泌的抑制作用减弱,与 TGF-β 型 II 受体减少相关。研究 TGF-β1 的激活过程及其调节对于理解细胞因子活性至关重要。作为多巴胺抑制催乳素功能的中介物,TGF-β1 和局部激活剂可能是治疗多巴胺激动剂抵抗性泌乳素瘤的重要靶点。

相似文献

1
Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.
Endocrinology. 2011 Jul;152(7):2722-30. doi: 10.1210/en.2010-1464. Epub 2011 Apr 26.
2
Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
Endocrinology. 2013 Nov;154(11):4192-205. doi: 10.1210/en.2013-1433. Epub 2013 Sep 5.
7
The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Mol Cell Endocrinol. 2015 Feb 15;402:64-71. doi: 10.1016/j.mce.2014.12.024. Epub 2015 Jan 8.
8
Activation of D2 dopamine receptors inhibits estrogen response element-mediated estrogen receptor transactivation in rat pituitary lactotrophs.
Mol Cell Endocrinol. 2013 Aug 15;375(1-2):58-67. doi: 10.1016/j.mce.2013.05.011. Epub 2013 May 20.
10
Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
J Clin Endocrinol Metab. 2003 Feb;88(2):858-63. doi: 10.1210/jc.2002-021281.

引用本文的文献

1
Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.
Front Endocrinol (Lausanne). 2024 Feb 2;15:1338345. doi: 10.3389/fendo.2024.1338345. eCollection 2024.
2
Revealing Sexual Dimorphism in Prolactin Regulation From Early Postnatal Development to Adulthood in Murine Models.
J Endocr Soc. 2023 Nov 28;8(1):bvad146. doi: 10.1210/jendso/bvad146. eCollection 2023 Dec 1.
3
Current and Emerging Medical Therapies in Pituitary Tumors.
J Clin Med. 2022 Feb 12;11(4):955. doi: 10.3390/jcm11040955.
6
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.
J Endocrinol. 2016 Mar;228(3):R73-83. doi: 10.1530/JOE-15-0451. Epub 2015 Dec 23.
7
Prolactin induces apoptosis of lactotropes in female rodents.
PLoS One. 2014 May 23;9(5):e97383. doi: 10.1371/journal.pone.0097383. eCollection 2014.
9
Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia.
Mol Biol Rep. 2013 Oct;40(10):5607-14. doi: 10.1007/s11033-013-2662-8. Epub 2013 Sep 25.
10
Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
Endocrinology. 2013 Nov;154(11):4192-205. doi: 10.1210/en.2013-1433. Epub 2013 Sep 5.

本文引用的文献

1
Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors.
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18758-63. doi: 10.1073/pnas.0805411105. Epub 2008 Nov 20.
4
Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma.
Front Horm Res. 2006;35:50-63. doi: 10.1159/000094308.
5
Genesis of prolactinomas: studies using estrogen-treated animals.
Front Horm Res. 2006;35:32-49. doi: 10.1159/000094307.
6
Regulation of pituitary hormones and cell proliferation by components of the extracellular matrix.
Braz J Med Biol Res. 2005 Oct;38(10):1487-94. doi: 10.1590/s0100-879x2005001000005. Epub 2005 Sep 6.
9
Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.
Endocrinology. 2005 Jul;146(7):2952-62. doi: 10.1210/en.2004-1445. Epub 2005 Apr 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验